Wednesday, November 30, 2016

Summer Project Turns Into Leukemia Testing Breakthrough; New York Times, 11/28/16

Donald G. McNeil Jr., New York Times; Summer Project Turns Into Leukemia Testing Breakthrough:
'Gleevec, which made almost $5 billion for Novartis last year, has been at the center of a long battle between pharmaceutical companies and activists fighting price increases. The drug cost about $26,000 per year in 2001, and Novartis repeatedly raised the price even as competitors emerged; early this year, it was more than $120,000.
Those who support broader access to medicines argue that poor countries should reject patents and make generic versions of leukemia drugs. In 2013, India’s highest court struck down Novartis’s patent application for Gleevec, opening the way for generics. They now cost about $400 a year in India and about $9,000 in Canada."

No comments:

Post a Comment